10-Q: Scholar Rock Reports Q2 Loss, Advances SMA Drug

Scholar Rock Holding Corporation reported increased net losses in Q2 2025 due to higher R&D and G&A expenses, while advancing its lead SMA drug, apitegromab, towards potential U.S. and European commercialization.

Summary

• Net loss for the six months ended June 30, 2025, was $184.8 million, compared to $115.4 million for the same period in 2024.
• Research and development expenses increased by $25.6 million (30.0%) to $111.1 million for the six months ended June 30, 2025, primarily due to increased drug supply manufacturing for apitegromab and preclinical costs for SRK-439.
• General and administrative expenses surged by $45.6 million (140.7%) to $78.1 million for the six months ended June 30, 2025, driven by increased headcount, one-time severance and equity-based compensation charges related to leadership changes, and higher professional service fees.
• Cash, cash equivalents, and marketable securities decreased by $142.3 million, from $437.3 million at December 31, 2024, to $295.0 million at June 30, 2025.
• Apitegromab's U.S. Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) is under priority review with a PDUFA target action date of September 22, 2025.
• A Marketing Authorisation Application (MAA) for apitegromab for SMA was submitted to and validated by the European Medicines Agency (EMA) in March 2025.
• Positive top-line results from the Phase 2 EMBRAZE trial for apitegromab in obesity were announced, showing 54.9% preservation of lean mass (+4.2 lbs) when combined with tirzepatide over 24 weeks (p=0.001).
• The Phase 1 DRAGON clinical trial for SRK-181 in cancer immunotherapy was completed in June 2025, showing encouraging responses in heavily pretreated and anti-PD-(L)1 resistant clear cell renal cell carcinoma (ccRCC) patients.
• An Investigational New Drug (IND) application for SRK-439, a novel anti-myostatin antibody, is planned for submission in the second half of 2025.
• The company expects to initiate the Phase 2 OPAL trial in SMA patients under two years of age in the third quarter of 2025.
• Scholar Rock will transition from a smaller reporting company to a large accelerated filer effective December 31, 2025, increasing compliance costs and demands.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong clinical trial results for apitegromab in both SMA and obesity, and promising data for SRK-181 in oncology, which represent significant progress in key programs. However, this is tempered by a substantial increase in net losses and operating expenses, a high cash burn rate, and the explicit need for future capital, which introduce financial uncertainty and potential dilution for investors.

Positives

• Apitegromab's BLA for SMA is under priority review by the FDA, with a PDUFA target action date of September 22, 2025, indicating potential for accelerated approval.
• The MAA for apitegromab for SMA was validated by the EMA, progressing towards European market authorization.
• Positive top-line results from the Phase 2 EMBRAZE trial demonstrated apitegromab's ability to preserve lean mass (54.9% preservation, +4.2 lbs) in obesity patients on GLP-1 RA therapy, achieving proof-of-concept.
• The Phase 1 DRAGON trial for SRK-181 in cancer was completed, showing encouraging and durable clinical responses in heavily pretreated anti-PD-(L)1 resistant ccRCC patients, exceeding expectations for PD-1 monotherapy.
• The company plans to initiate the Phase 2 OPAL trial for SMA patients under two years of age in Q3 2025, expanding apitegromab's potential indications.
• SRK-439, a new anti-myostatin program, is advancing towards an IND submission in H2 2025, indicating pipeline expansion.

Negatives

• Net loss significantly increased to $184.8 million for the six months ended June 30, 2025, from $115.4 million in the prior year period.
• Operating expenses rose substantially, with R&D increasing by 30.0% and G&A by 140.7% for the six months ended June 30, 2025.
• Cash, cash equivalents, and marketable securities decreased by $142.3 million in the first six months of 2025, indicating a high cash burn rate.
• One-time severance and equity-based compensation charges totaling $16.1 million were incurred due to leadership changes.
• The company has an accumulated deficit of $1,107.5 million as of June 30, 2025, reflecting sustained historical losses.
• The company will require additional capital to complete clinical development and commercialization for its programs, indicating future dilution or debt.

Risks

• The regulatory approval process for product candidates is lengthy, time-consuming, and inherently unpredictable, with no guarantee of approval or timely approval.
• Lack of prior commercialization experience and challenges in building and scaling commercial infrastructure could negatively impact successful product launches.
• Disruptions at regulatory agencies (e.g., FDA) due to funding cuts or policy changes could delay BLA review and approval.
• Clinical trials are expensive, lengthy, and uncertain, with potential for delays, failures to meet endpoints, or safety concerns.
• Interim or preliminary clinical trial results may not be predictive of final data and are subject to change.
• Reliance on a limited number of third-party manufacturers and suppliers poses risks of supply limitations, interruptions, or quality issues.
• Economic uncertainty, geopolitical instability, high inflation, and interest rates could adversely affect business operations and supply chains.
• Difficulties in managing organizational growth, attracting, and retaining highly skilled personnel, especially during management transitions.
• Vulnerability of internal and third-party computer systems to security breaches, incidents, or compromises.
• Risks of employee misconduct, noncompliance with regulatory standards, and healthcare fraud and abuse laws.
• Ongoing healthcare legislative and regulatory reforms could adversely affect product pricing, coverage, and reimbursement.
• Potential for product liability lawsuits, which could result in substantial liabilities and limit commercialization.
• Concentration of laboratory operations in one location increases vulnerability to business interruptions and natural disasters.
• Uncertainty regarding insurance coverage and adequate reimbursement from third-party payors for approved products.
• Challenges in protecting intellectual property, including potential for patent invalidation, infringement claims, and trade secret misappropriation.
• The company's ability to use net operating loss carryforwards and tax credit carryforwards may be limited by ownership changes.
• Adverse developments in the financial services industry could impair access to funding sources and liquidity.
• Restrictions on operating and financial flexibility due to terms of the loan and security agreement.
• Stock price volatility and potential for substantial dilution from the exercise of warrants and equity awards.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it develops commercialization capabilities, continues apitegromab development (including the ONYX and planned OPAL trials), advances the anti-myostatin program (SRK-439 IND submission in H2 2025), discovers new product candidates, and builds public company infrastructure. Commercial product launch of apitegromab in the U.S. is expected in Q4 2025 if approved, with Europe to follow in 2026. Existing cash, cash equivalents, and marketable securities are projected to fund operations into 2027, but additional capital will be required to complete clinical development and commercialization of current programs.

Management Comments

• We believe that apitegromab has the potential to be the first muscle-targeted treatment that is aimed at improving motor function in patients with SMA who are receiving an SMN-targeted therapy.
• We expect to initiate a commercial product launch in the fourth quarter of 2025 in the United States, with a commercial launch of apitegromab in Europe anticipated to follow in 2026.
• We plan to initiate the Phase 2 OPAL trial in SMA patients under two years of age in the third quarter of 2025.
• We are developing SRK-439 towards a potential investigational new drug application (IND) submission in the second half of 2025.
• We believe that the DRAGON trial achieved its study objectives by showing objective, durable clinical responses in patients with ccRCC resistant to PD-1 therapy above what is expected from continuing PD-1 alone.
• We expect general and administrative expense to continue to be substantial as we continue to invest in building the infrastructure to support the commercialization of apitegromab.

Industry Context

Scholar Rock operates in the highly competitive biopharmaceutical industry, focusing on rare neuromuscular diseases like SMA, and expanding into cardiometabolic disorders (obesity) and oncology. The positive Phase 2 EMBRAZE trial results for apitegromab in obesity, particularly its lean mass preservation effect when combined with GLP-1 RAs like tirzepatide, position the company in a rapidly growing and high-interest area of metabolic health, potentially differentiating it from existing weight-loss therapies that can lead to significant lean mass loss. The completion of the SRK-181 Phase 1 trial in checkpoint inhibitor-resistant cancers addresses a critical unmet need in oncology, where resistance mechanisms limit the effectiveness of current immunotherapies. The company's proprietary TGFβ superfamily platform aims to overcome historical safety challenges by selectively targeting latent growth factors, a unique approach in the field.

Comparison to Industry Standards

• Apitegromab's 54.9% preservation of lean mass (+4.2 lbs) in the EMBRAZE trial, when combined with tirzepatide, compares favorably to typical GLP-1 RA treatments alone, which often result in a higher proportion of weight loss from lean mass. For example, studies on tirzepatide monotherapy have shown that a significant portion of total weight loss can come from lean body mass, making apitegromab's effect a potential differentiator in the obesity treatment landscape.
• The positive top-line results from the SAPPHIRE Phase 3 trial for apitegromab in non-ambulatory SMA, achieving its primary endpoint, positions it as a potential first muscle-targeted treatment for SMA, complementing existing SMN-targeted therapies like Biogen's Spinraza (nusinersen) and Roche's Evrysdi (risdiplam). These existing therapies primarily target SMN protein production, while apitegromab targets myostatin to improve muscle function, suggesting a potentially synergistic or additive benefit.
• SRK-181's encouraging responses in heavily pretreated and anti-PD-(L)1 resistant clear cell renal cell carcinoma (ccRCC) patients in the DRAGON trial are notable, as this patient population typically has limited treatment options and poor prognosis after failing standard checkpoint inhibitors. This suggests a potential for SRK-181 to address a significant unmet need in a challenging oncology setting, where current standards of care offer less robust outcomes for resistant cases.

Management Changes

Corporate Governance

Legal Proceedings

• The company was not subject to any material legal proceedings during the six months ended June 30, 2025 and 2024.
• The company may be party to litigation arising in the ordinary course of business from time to time.

Stakeholder Impact

• Shareholders: Face increased net losses and cash burn, but also potential for significant value creation if apitegromab gains regulatory approval and market acceptance. Future capital raises may lead to dilution. Stock price volatility is a risk.
• Employees: Significant management changes have occurred, with new executives appointed. Increased headcount and associated costs are noted, indicating growth in the workforce. Severance and equity modification charges impact employee-related expenses.
• Patients (SMA): Apitegromab's progress towards regulatory approval in the U.S. and Europe offers hope for a new muscle-targeted treatment option, potentially improving motor function.
• Patients (Obesity): Positive Phase 2 data for apitegromab in obesity suggests a potential new therapy to address lean mass preservation during weight loss, offering a differentiated benefit.
• Creditors: The company refinanced its debt facility, extending the interest-only period and maturity date, which provides more financial flexibility but also indicates continued reliance on debt.

Next Steps

• Initiate commercial product launch of apitegromab in the United States in the fourth quarter of 2025, if approved by the FDA.
• Anticipate commercial launch of apitegromab in Europe in 2026.
• Initiate the Phase 2 OPAL trial in SMA patients under two years of age in the third quarter of 2025.
• Submit an Investigational New Drug (IND) application for SRK-439 in the second half of 2025.
• Continue to invest in building the infrastructure to support the commercialization of apitegromab.
• Continue to discover, validate, and develop additional product candidates through the proprietary platform.
• Maintain, expand, and protect the intellectual property portfolio.
• Hire additional research, development, commercial, and other business personnel.
• Continue to build the infrastructure to support operations as a public company, especially with the transition to a large accelerated filer.

Key Dates

Recommendation

Scholar Rock presents a mixed bag for investors. The positive clinical trial results for apitegromab in SMA and obesity, along with the completion of the SRK-181 trial, demonstrate strong progress in the pipeline and validate the company's platform. The priority review for apitegromab's BLA is a significant positive catalyst. However, the substantial increase in net losses and operating expenses, coupled with a high cash burn rate and the explicit need for additional capital, introduce considerable financial risk. The upcoming transition to a large accelerated filer status will also add to operational costs and complexity. Given the promising clinical developments balanced against the significant financial challenges and the need for future funding, a 'hold' recommendation is appropriate. Investors should monitor the PDUFA decision for apitegromab, commercial launch progress, and future capital raising activities.

Keywords

Biopharmaceutical, Spinal Muscular Atrophy, SMA, Apitegromab, Myostatin inhibitor, Obesity, GLP-1 RA, Cancer immunotherapy, TGFβ1 inhibitor, SRK-181, SRK-439, Clinical trials, FDA approval, EMA validation, Drug development, Biotech, Rare disease, Neuromuscular disorders, Oncology, Metabolic disorders